A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of ...

Use of GLP-1 drugs for weight loss rose sharply in kids and adolescents after the American Academy of Pediatrics in 2023 recommended offering medications along with lifestyle adjustments such as ...

Research indicates GLP-1 receptor agonists, like Ozempic, may elevate testosterone levels in men while promoting weight loss. A study presented at ENDO 2025 showed a significant increase in ...

Popular anti-obesity medications continue to be effective for weight loss even when availability and access is interrupted, ...

Popular anti-obesity medications continue to be effective for weight loss even when availability and access is interrupted, according to ...

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...

New study published by Truveta and Harvard Medical School A groundbreaking study published today in Pediatrics Open Science ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.